Perceptive Advisors LLC Takes Position in Gilead Sciences, Inc. (GILD)

Perceptive Advisors LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, HoldingsChannel.com reports. The fund bought 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,241,000.

Several other large investors have also bought and sold shares of GILD. BlackRock Inc. boosted its holdings in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after buying an additional 1,937,031 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Gilead Sciences by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after buying an additional 310,607 shares during the last quarter. FMR LLC boosted its holdings in Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares during the last quarter. Hedge funds and other institutional investors own 75.84% of the company’s stock.

In related news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total value of $2,087,750.00. Following the completion of the sale, the executive vice president now owns 62,738 shares in the company, valued at approximately $5,239,250.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. Insiders sold a total of 578,333 shares of company stock valued at $44,100,508 in the last quarter. 1.30% of the stock is owned by insiders.

Shares of Gilead Sciences, Inc. (GILD) opened at $80.38 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market cap of $102,372.30, a P/E ratio of 9.15, a PEG ratio of -1.73 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter last year, the firm earned $2.70 EPS. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 2.84%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.

Several equities research analysts recently issued reports on GILD shares. William Blair reiterated a “buy” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Mizuho lifted their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $73.67 to $94.00 in a report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $85.58.

WARNING: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2018/02/07/perceptive-advisors-llc-takes-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit